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Abstract
Campylobacter is a major foodborne pathogen in humans and a significant cause of abortion in sheep.
Although ruminants are increasingly recognized as important reservoirs for Campylobacter, limited
information is available about the molecular epidemiology and antimicrobial resistance (AMR) profiles of
sheep Campylobacter. Here we describe a two-trial study that examined Campylobacter profiles in sheep and
determined whether in-feed tetracycline influenced the distribution and AMR profiles of Campylobacter. Each
trial involved 80 commercial sheep naturally infected with Campylobacter, 40 of which were medicated with
tetracycline in feed, while the other 40 received feed without antibiotics. Fecal and bile samples were collected
for the isolation of Campylobacter. The bacterial isolates were analyzed for antimicrobial susceptibility and
genotypes. The results revealed that 87.0% and 61.3% of the fecal and bile samples were positive for
Campylobacter (C. jejuni and C. coli), with no significant differences between the medicated and non-
medicated groups. All but one of the tested Campylobacter isolates were resistant to tetracycline. Although
fluoroquinolone (FQ) resistance remained low in C. jejuni (1.7%), 95.0% of the C. coli isolates were resistant
to FQ. Genotyping revealed that C. jejuni ST2862 and C. coli ST902 were the predominant genotypes in the
sheep. Feed medication with tetracycline did not affect the overall prevalence, species distribution and AMR
profiles of Campylobacter, but increased the total Campylobacter counts in bile and gallbladder. These findings
identify predominant Campylobacter clones, reveal the high prevalence of FQ-resistant C. coli, and provide
new insights into the epidemiology of Campylobacter in sheep.
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Abstract 23 
Campylobacter is a major foodborne pathogen in humans and a significant cause of abortion in 24 
sheep. Although ruminants are increasingly recognized as important reservoirs for 25 
Campylobacter, limited information is available about the molecular epidemiology and 26 
antimicrobial resistance (AMR) profiles of sheep Campylobacter. Here we describe a two-trial 27 
study that examined Campylobacter profiles in sheep and determined whether in-feed 28 
tetracycline influenced the distribution and AMR profiles of Campylobacter. Each trial involved 29 
80 commercial sheep naturally infected with Campylobacter, 40 of which were medicated with 30 
tetracycline in feed, while the other 40 received feed without antibiotics. Fecal and bile samples 31 
were collected for the isolation of Campylobacter. The bacterial isolates were analyzed for 32 
antimicrobial susceptibility and genotypes. The results revealed that 87.0% and 61.3% of the 33 
fecal and bile samples were positive for Campylobacter (C. jejuni and C. coli), with no 34 
significant differences between the medicated and non-medicated groups. All but one of the 35 
tested Campylobacter isolates were resistant to tetracycline. Although fluoroquinolone (FQ) 36 
resistance remained low in C. jejuni (1.7%), 95.0% of the C. coli isolates were resistant to FQ. 37 
Genotyping revealed that C. jejuni ST2862 and C. coli ST902 were the predominant genotypes 38 
in the sheep. Feed medication with tetracycline did not affect the overall prevalence, species 39 
distribution and AMR profiles of Campylobacter, but increased the total Campylobacter counts 40 
in bile and gallbladder. These findings identify predominant Campylobacter clones, reveal the 41 
high prevalence of FQ-resistant C. coli, and provide new insights into the epidemiology of 42 
Campylobacter in sheep. 43 
Keywords: Campylobacter, sheep, antimicrobial resistance, genotype, fluoroquinolone 44 
 45 
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Importance 46 
Campylobacter is a major cause of foodborne illness in humans and antibiotic-resistant 47 
Campylobacter is considered a serious threat to public health in the United States and 48 
worldwide. As a foodborne pathogen, Campylobacter commonly exists in the intestinal tract of 49 
ruminant animals such as sheep and cattle. Results from this study reveal the predominant 50 
genotypes and high prevalence of tetracycline and fluoroquinolone resistance in sheep 51 
Campylobacter. The finding on fluoroquinolone resistance in sheep Campylobacter is 52 
unexpected as this class of antibiotics is not used for sheep in the United States, and it may 53 
suggest the transmission of fluoroquinolone-resistant Campylobacter from cattle to sheep. 54 
Additionally, the results demonstrate that in-feed medication with tetracycline increases 55 
Campylobacter counts in gallbladders, suggesting that the antibiotic promotes Campylobacter 56 
colonization of gallbladder. These findings provide new information on Campylobacter 57 
epidemiology in sheep, which may be useful for curbing the spread of antibiotic-resistant 58 
Campylobacter in animals reservoirs. 59 
   60 
Introduction 61 
Campylobacter species, particularly Campylobacter jejuni and Campylobacter coli, are a 62 
leading cause of bacterial foodborne gastroenteritis in humans around the world (1-3). Among all 63 
the causes of laboratory-confirmed bacterial food-borne illnesses, Campylobacter was the 64 
leading cause (19.2 per 100,000 population) in the year of 2017 based on the report by the 65 
Centers for Disease Control and Prevention (CDC)’s FoodNet surveillance program in the 66 
United States (4). Although most Campylobacter-related illnesses in humans are characterized as 67 
self-limiting diarrhea (watery and/or bloody), antibiotic treatment is utilized in more severe 68 
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clinical conditions, especially in young, elderly, or immunocompromised patients (5). However, 69 
antimicrobial resistance in Campylobacter is increasingly prevalent and has become a major 70 
public health concern in both developed and developing counties (6, 7). Of particular concern is 71 
the rising resistance to fluoroquinolone (FQ) and macrolide antibiotics, which are clinically 72 
important for the treatment of Campylobacter induced diarrhea in humans, but in some cases, 73 
tetracyclines and gentamicin are also used to treat systemic infection caused by Campylobacter 74 
(6, 8, 9). 75 
Food-producing animals are important reservoirs for Campylobacter (10). Epidemiologically, 76 
poultry meat is considered the major source of infection for human campylobacteriosis (11). C. 77 
jejuni and C. coli frequently colonize the intestines of many species of poultry, especially 78 
commercial chickens and turkeys, usually as part of the normal microbial flora without causing 79 
clinical disease (12). Recently, the role of ruminants (cattle and sheep) in Campylobacter 80 
ecology has been increasingly recognized in different countries (13-17). Ruminant 81 
Campylobacter can be transmitted to humans via contaminated milk and water, environmental 82 
contamination or direct contact with animals (18). Source attribution studies indicate that 83 
ruminant Campylobacter is a significant source of infection for human campylobacteriosis (19-84 
21).   85 
Typically, Campylobacter colonizes in the intestinal tract in animals, but it may also 86 
translocate across the intestinal epithelial barrier and causes systemic infection, such as 87 
bacteremia and abortion in ruminants and even in humans occasionally (1, 22). In fact, 88 
Campylobacter is the major cause of ovine abortions worldwide, including the U.S. Notably, a 89 
single hypervirulent tetracycline-resistant C. jejuni clone (named clone SA for sheep abortion) is 90 
responsible for the majority of Campylobacter-associated ovine abortions in the U.S. (17, 23, 91 
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24). Previous survey of healthy sheep in a slaughterhouse revealed genetically diverse C. jejuni 92 
strains (including clone SA) present in the intestinal tract and gallbladder (25). Despite the fact 93 
that ruminants are increasingly recognized as important reservoirs for Campylobacter, limited 94 
information is available about the molecular epidemiology and antimicrobial resistance profiles 95 
of sheep Campylobacter in the United States.  96 
 For the control of abortion and other diseases, the tetracycline class of antibiotics is 97 
commonly used in the U.S., and it is the only class of antibiotics approved for prevention and 98 
control of sheep abortion associated with Campylobacter (23). However, whether the 99 
administration of tetracycline in feed impacts the prevalence of Campylobacter in sheep is not 100 
known. Previously, it was shown that sheep harbored diverse strains of C. jejuni that were 101 
commonly resistant to tetracycline; however, resistance to FQ was seldomly detected (25). 102 
Recently, FQ resistance in cattle Campylobacter isolates has increased substantially in the U.S. 103 
(15, 26-28). However, detection of FQ resistance in sheep Campylobacter isolates is still limited. 104 
To address these knowledge gaps, we collected samples and isolated Campylobacter from 105 
controlled treatment (feed medication with tetracycline) studies using sheep that were derived 106 
from commercial operations and were naturally infected by Campylobacter. The goals were to 107 
examine the extent of FQ resistance in sheep Campylobacter and determine the effect of in-feed 108 
tetracycline on the prevalence, species distribution, and antimicrobial resistance profiles of 109 
Campylobacter in sheep.   110 
Materials and Methods 111 
Sample collection and Campylobacter isolation  112 
Two separate trials were conducted and each involved 80 feeder lambs, with 40 each in the 113 
feed medicated group and feed non-medicated group. These sheep were purchased from two 114 
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commercial farms and then housed in the laboratory animal facility at Iowa State University 115 
during the treatment study. Trial 1 was conducted using animals from farm 1, while trial 2 was 116 
performed using animals from Farm 2. The two farms are in the Midwest region and are 117 
geographically separated by approximately 86 miles. The ages of the sheep at enrolment varied, 118 
but all were spring-born feeder lambs and approximately two months old. Both source farms 119 
raise sheep in a semi-intensive management program with outdoor access. Treatment of sheep 120 
with FQ antibiotics is expressly prohibited in the U.S. and there was no history of use of these 121 
antibiotics on these farms.  122 
In each trial, the animals were randomly assigned into the feed medicated and non-medicated 123 
groups. Chlortetracycline (Aureomycin, Zoetis) was used for the feed medication, and the 124 
medication was conducted to determine the effect of the antibiotic on prevention and control of 125 
bacterial pneumonia in feedlot lambs. The antibiotic was fed extra-label (350 mg/hd/d; 160 126 
mg/kg body weight or 160 ppm in feed) in accordance with the FDA/CVM’s Guidance 615.115. 127 
Regardless of the feed medication, clinically sick animals (19 in each group for trial 1; 17 and 128 
18, respectively, for trail 2) received a chlortetracycline injection (9 mg/lb) and the injection 129 
repeated once in 72 hr if needed. The treated sheep remained in their respective groups.  130 
Trial 1 was performed from June 21, 2017 to July 6, 2017, while Trial 2 was carried out from 131 
July 13, 2017 to July 26, 2017 (Table 1). Fecal samples were collected at the beginning of the 132 
study and once a week thereafter. Bile and gallbladder samples were collected at necropsy. The 133 
samples were then cultured for Campylobacter using Mueller–Hinton (MH) agar plates (Difco) 134 
with selective antimicrobials and growth supplements (SR084E and SR117E; Oxoid). The plates 135 
were incubated at 42 °C for 48 h under microaerobic conditions (85% N2, 5% O2 and 10% 136 
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CO2). Up to three Campylobacter-like colonies from each sample were subcultured onto MH 137 
agar plates and the pure cultures were stored in glycerol stocks at −80 °C.  138 
Enumeration of Campylobacter in bile and gallbladder mucosa           139 
In addition to isolation of Campylobacter from individual bile samples as described above, 140 
we also determined the total Campylobacter colony forming units (CFUs) in bile and gallbladder 141 
mucosa. For this purpose, bile and gallbladder samples were randomly collected from sheep at 142 
necropsy in the two trials. In total, 37 and 35 bile/gallbladder mucosal samples were selected in 143 
the two trials from the feed non-medicated and feed medicated groups, respectively. For each 144 
group, the sheep were housed in 4 separate pens and the collected bile from each gallbladder (5-145 
15 ml) was pooled based on treatment group and pen number. In total, 4 pools were obtained per 146 
group in each trial. For collection of gallbladder mucosal samples, 5 ml of PBS was used to wash 147 
any residual bile off each gallbladder mucosa. Then, a sterile razor blade was used to scrape 148 
mucosa from each gallbladder onto a bile-free weigh boat. Next, the blade was washed with PBS 149 
to rinse any mucosa on the blade onto the weigh boat, which then was rinsed with roughly 2 ml 150 
of PBS, and the collected gallbladder mucosa was decanted into a 15 ml conical tube. The final 151 
volume was adjusted to 3 ml, and the 15 ml conical tube was vortexed vigorously prior to culture 152 
for Campylobacter.   153 
    For both the bile and gallbladder mucosal samples, a ten-fold dilution series was performed 154 
using 1.5 ml snap cap tubes filled with 900 μl of MH broth. Each dilution was spread onto MH 155 
agar plates containing selective supplement (SR084E; Oxoid) and standard culture conditions for 156 
Campylobacter were utilized as for the fecal samples (described above). After culturing, the 157 
Campylobacter CFUs were counted for each sample and the Log10 average was computed for 158 
both bile and gallbladder mucosa respectively. The detection limit of the plating method was 100 159 
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CFU/mL of bile or gallbladder mucosal suspension. All of the 16 pooled bile samples 160 
demonstrated visually pure growth of Campylobacter sp. and were utilized in the final 161 
calculations. For the gallbladder mucosal samples, 4 in the non-medicated group and 9 in the 162 
medicated group were not usable because of high background bacterial contamination after 163 
culturing. The remaining plates were visually determined to have pure growth of Campylobacter 164 
sp. and thus were used in the final calculations. In total, Campylobacter CFU counts were 165 
obtained from 33 and 26 gallbladder mucosal samples in the non-medicated and medicated 166 
groups, respectively. Representative colonies from each group were selected and subjected to 167 
species confirmation and identification (see below).    168 
Bacterial species identification  169 
Matrix-assisted laser desorption ionization time-of-flight (MALDI-TOF) mass spectrometry 170 
(Bruker) was used for bacterial species identification. All isolates were identified to the species 171 
level. Sample preparation and analysis were done as described previously (29). Mass spectra 172 
were acquired and analyzed using a microflex LT mass spectrometer (Bruker Daltonics) in 173 
combination with research-use-only version of the MALDI Biotyper Compass software 4.1 and 174 
the reference database MBT 7311 MSP Library (#1829023) at Iowa State University. Data were 175 
interpreted in accordance with the manufacturer’s (Bruker Daltonics) standard criteria: a) high-176 
confidence identification when the score was between 2.00 and 3.00, b) low-confidence 177 
identification when the score was between 1.70 and 1.99, and c) no organism identification 178 
possible when the score was 1.69 and lower.  179 
C. jejuni Clone SA detection 180 
PCR was used for identifying C. jejuni clone SA. DNA template was extracted from 181 
Campylobacter colonies using single-cell lysis buffer (30). Primers specific for C. jejuni clone 182 
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SA were designed as described previously (31). C. jejuni IA3902, a clinical isolate of clone SA, 183 
was used as the positive control, while a reaction without template DNA served as a negative 184 
control. 185 
Antimicrobial susceptibility testing 186 
A total of 236 C. jejuni and 101 C. coli non-duplicate isolates from fecal samples were tested 187 
for antimicrobial susceptibility. Those isolates were representatives of individual animals at 188 
different sampling times. Also, 98 C. jejuni and 2 C. coli non-duplicate isolates (a single isolate 189 
from each animal) from bile samples were included in the susceptibility testing. The minimum 190 
inhibitory concentrations (MICs) of nine antibiotics were determined using a standard broth 191 
microdilution method as recommended by CLSI and the National Antimicrobial Resistance 192 
Monitoring System for Enteric Bacteria (NARMS) (32-34). The tested ranges and breakpoints of 193 
the nine antibiotics were listed in Table S1. Commercially available Sensititre Campylobacter 194 
plates (ThermoFisher Scientific, Waltham, MA) were used for the tests. The nine antibiotics 195 
were azithromycin (AZI), ciprofloxacin (CIP), erythromycin (ERY), gentamicin (GEN), 196 
tetracycline (TET), florfenicol (FFN), nalidixic acid (NAL), telithromycin (TEL) and 197 
clindamycin (CLI). After incubation in a microaerobic environment for 24 h at 42 °C, the results 198 
were interpreted. For each isolate, MIC values were set as the lowest antimicrobial concentration 199 
at which no bacterial growth was observed. The antimicrobial resistance breakpoints were 200 
chosen according to the standards established by the CLSI for bacteria isolated from animals (32-201 
34). C. jejuni ATCC 33560 and C. coli ATCC 33559 were used as quality control strains, 202 
respectively. 203 
PFGE and MLST typing of Campylobacter isolates 204 
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Representative Campylobacter isolates were analyzed by using pulsed-field gel 205 
electrophoresis (PFGE) and multilocus sequence typing (MLST). PFGE analysis of the 206 
macrorestriction fragment patterns of genomic DNA using KpnI enzyme was performed 207 
following the CDC’s standardized PulseNet protocol for Campylobacter with minor 208 
modifications (23). Briefly, fresh cultures of Campylobacter were embedded in 1% Seakem Gold 209 
agarose (Fisher Scientific, Fair Lawn, NJ) and lysed with proteinase K for 30 minutes at 50 °C in 210 
a water bath shaker. The gel plugs were digested with KpnI for 4 h at 37 °C. Digested plugs were 211 
embedded into 1% agarose and separated by electrophoresis in 0.5 × TBE buffer (Promega) at 14 212 
°C for 18 h using a Chef Mapper electrophoresis system (Bio-Rad, Hercules, CA). The gels were 213 
stained with ethidium bromide for 30 min and then photographed using a digital imager (Alpha 214 
Innotech, Santa, Clara, CA). The PFGE patterns were analyzed by the GelCompare II v.6.5 215 
software (Applied Maths, Kortrijk, Belgium) using Dice similarity coefficient and unweighted-216 
pair group method with arithmetic averages (UPGMA) with 0.5% optimization and 1.5% 217 
position tolerance. Lambda DNA ladder (Bio-Rad) was used as the molecular size marker. PFGE 218 
patterns with ≥90% similarity was defined as a cluster.  219 
To further confirm the genetic diversity of the isolates, MLST was performed for selected 220 
representative isolates of different PFGE patterns as described previously (35). The seven 221 
housekeeping genes were amplified and sequenced using the primers recommended by the 222 
Campylobacter MLST website (https://pubmlst.org/campylobacter/), which was developed by 223 
Keith Jolley and Man-Suen Chan at the University of Oxford (36). All PCR products were 224 
purified using the QIAquick® PCR purification kit (QIAGEN, Hilden, Germany) and then 225 
sequenced at the DNA Core Facility of Iowa State University using an Applied Biosystems 226 
3730xl DNA Analyzer. The sequences were submitted to the MLST database to determine allele 227 
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numbers and STs. The new allele and STs were submitted to the database and were assigned new 228 
numbers. 229 
gyrA mutation determination 230 
In Campylobacter, FQ resistance is conferred by point mutations in the gyrA gene in 231 
conjunction with the CmeABC efflux pump (37). To confirm the mechanism of FQ resistance in 232 
this study, four FQR C. jejuni isolates and eight FQR C. coli isolates of different PFGE and 233 
MLST types were selected for determination of the point mutations in the quinolone resistance 234 
determining region (QRDR) of gyrA. The primers GyrAF1 (5′-CAACTGGTTCTAGCCTTTTG-235 
3) and GyrAR1 (5-AATTTCACTCATAGCCTCACG-3) were used for C. jejuni isolates, while 236 
GyrAF2 (5-TTATTTAGATTATTCTATGAGCGT-3) and GyrAR2 (5-237 
CTTGAGTTCGATTACAACAC-3) were used for C. coli isolates as described previously (15). 238 
All PCR products were purified using the QIAquick® PCR purification kit (QIAGEN, Hilden, 239 
Germany) and then sequenced at the DNA Core Facility of Iowa State University using an 240 
Applied Biosystems 3730xl DNA Analyzer.  241 
Statistical analysis 242 
Chi-square test and Fisher’s exact test were used to compare the prevalence and the 243 
antimicrobial resistance rates of the Campylobacter isolates from different samples (fecal and 244 
bile samples) and different groups (feed non-medicated and medicated groups). Unpaired t-test 245 
was used to compare the average Campylobacter CFU/ml results from the bile and gallbladder 246 
mucosal samples between the non-medicated and medicated groups in two trials. The data was 247 
analyzed using GraphPad (Prism). P values less than 0.05 were deemed to be statistically 248 
significant.  249 
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Results 250 
Prevalence of Campylobacter in sheep 251 
In total, 461 sheep fecal samples and 160 bile samples were collected for isolation of 252 
Campylobacter in the two separate trials. The overall prevalence rate of Campylobacter in sheep 253 
feces was 87.0% (401/461). Among the positive samples, 68.6% (275/401) and 37.4% (150/401) 254 
were positive for C. jejuni and C. coli, respectively, and 24 fecal samples were positive for both 255 
C. jejuni and C. coli (Table 1).The overall prevalence of Campylobacter in fecal samples was 256 
comparable (71.8% vs. 65.3% for C. jejuni; 33.2% vs. 41.7% for C. coli) between the feed 257 
medicated and non-medicated groups (p > 0.05).(Table 1). Among the bile samples, 61.3% 258 
(98/160) were positive for Campylobacter (Table 2). Of the Campylobacter isolates, 98.0% 259 
(96/98) were C. jejuni, and 2.0% (2/98) were C. coli. The two C. coli isolates from bile were 260 
both isolated from the feed medicated group in Trial 2 (Table 2). Again, there was no significant 261 
difference (P > 0.05) between the groups in the prevalence of either C. jejuni (100% vs. 95.8%) 262 
or C. coli (0% vs. 4.2%). These results indicate that the in-feed tetracycline medication did not 263 
affect the overall prevalence of Campylobacter in fecal and bile samples. 264 
Statistically, the overall Campylobacter prevalence was higher in fecal samples than in bile 265 
samples (87.0% vs. 61.3%, P < 0.05). However, the proportion of C. jejuni was significantly (P 266 
< 0.05) lower in feces than in bile (68.6% vs. 98.0%), while the proportion of C. coli was higher 267 
in feces than in bile (37.4% vs. 2.0%). Detailed information about the prevalence of 268 
Campylobacter and the distribution of C. jejuni and C. coli is summarized in Tables 1 and 2. We 269 
analyzed all of the C. jejuni isolates from feces and bile by PCR for identification of C. jejuni 270 
clone SA, and none of them were positive, indicating clone SA was not present in the sheep used 271 
in this study. 272 
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Quantitative measurement of Campylobacter CFUs in bile and gallbladder mucosa     273 
Significant differences in Campylobacter numbers (CFU/ml) between the feed medicated 274 
and non-medicated groups were detected for both the bile and gallbladder mucosal samples, with 275 
numbers higher in the medicated group (Figure 1). In the bile samples, the mean logCFU/ml ± 276 
SEM (standard error of the mean) were 5.041±0.281 and 6.021±0.108 in non-medicated and 277 
medicated group, respectively, indicating an almost 10-fold difference. The difference between 278 
the two groups was statistically significant [t(3.252,6) =0.0174, P < 0.05]. For the gallbladder 279 
mucosal samples, the mean logCFU/ml ± SEM of gallbladder mucosal samples were 280 
4.7239±0.2932 and 5.823±0.2611 in the non-medicated and medicated groups, respectively, 281 
again indicating an approximately 10-fold difference. The difference was also statistically 282 
significantly [t(2.722,57) = 0.0086, P < 0.05]. These results indicated that Campylobacter titers 283 
are higher in the gallbladder and bile samples taken from the feed medicated group. 284 
Antimicrobial susceptibility of the Campylobacter isolates 285 
For the tested fecal C. jejuni isolates (n=236), all (100%) were resistant to tetracycline, but 286 
the resistance rates to ciprofloxacin and nalidixic acid were low, at 1.7% (4/236) and 3.0% 287 
(7/236), respectively. All four ciprofloxacin-resistant (CIPR) C. jejuni isolates were derived from 288 
Trial 2. One C. jejuni isolate from the non-medicated group in Trial 1 showed resistance to 289 
gentamicin. The fecal C. coli isolates also showed a high resistance rate to tetracycline (99.0%; 290 
100/101), with only one sensitive to this antibiotic. In contrast to C. jejuni, the C. coli isolates 291 
were highly resistant to ciprofloxacin (95.0%; 96/101) and nalidixic acid (95.0%; 96/101). 292 
Resistance to the other five antibiotics were not observed. The key MIC results are shown in 293 
Table 3, while other relevant MIC data (MIC ranges, MIC50, and MIC90) were presented in 294 
Table S1. 295 
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For the isolates from bile samples, all tested C. jejuni were resistant to tetracycline (100.0%, 296 
96/96), but susceptible to other antibiotics, while the two C. coli isolates were resistant to 297 
tetracycline, ciprofloxacin and nalidixic acid. None of the bile C. jejuni or C. coli isolates 298 
showed resistance to gentamicin, azithromycin, erythromycin, florfenicol, telithromycin or 299 
clindamycin.  300 
Notably, the CIP resistance rate (95.0%) in C. coli is significantly (P < 0.05) higher than in 301 
C. jejuni (1.7%) for the fecal samples. There is no significant difference (P > 0.05) in the overall 302 
antimicrobial susceptibility profiles as tested in this study between fecal and bile C. jejuni. The 303 
two C. coli isolates from bile samples also showed similar resistance patterns to the C. coli 304 
isolates from feces. In addition, there was also no significant difference (P > 0.05) in the 305 
antimicrobial resistance rates of C. jejuni and C. coli between the feed non-medicated and feed 306 
medicated groups.  307 
Genetic diversity of the Campylobacter isolates from sheep 308 
In total, 24 C. coli and 39 C. jejuni isolates were selected for PFGE analysis. The twenty-four 309 
C. coli consisted of twelve CIPR C. coli from feces (one representative isolate for each group and 310 
each sampling time in the two trials), the two CIPR C. coli isolates from bile, the five CIPS fecal 311 
C. coli, the TET susceptible C. coli and the other four fecal C. coli (isolated from the same sheep 312 
with the two CIPR C. coli isolates from bile). The 24 C. coli isolates were grouped into three 313 
separate clusters, with the vast majority of isolates (75.0%, 18/24) grouped into type Ⅲ (Figure 314 
2). The five CIPS C. coli isolates were all in type Ⅰ, and type Ⅱ included one CIPR C. coli from 315 
feces. The predominated cluster (type Ⅲ) consisted of 18 CIPR C. coli, among which 16 were 316 
from fecal samples (including one TET susceptible isolate and 4 from the same sheep where the 317 
two CIPR bile isolates were obtained) and two from bile samples (Figure 2). MLST analysis 318 
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showed that the C. coli isolates grouped in type Ⅰ, Ⅱ, Ⅲ belong to ST827, ST1068 and ST902, 319 
respectively (Figure 2), consistent with the classifications using PFGE. Thus, ST902 was the 320 
most prevalent ST type in the sheep C. coli analyzed in this study. Interestingly, the CIPR bile 321 
and fecal isolates from the same sheep shared the same PFGE type (III) and MLST type 322 
(ST902), indicating the bile and fecal isolates are genetically related.  323 
The 39 C. jejuni included twelve CIPS C. jejuni from bile (three representative isolates for 324 
each group in two trials), the four CIPR C. jejuni from feces, the three CIPS fecal C. jejuni 325 
(isolated from the same sheep with the CIPR isolates), twenty CIPS fecal C. jejuni isolates (from 326 
different sheep that CIPR isolates were isolated, representative isolates from each group and each 327 
sampling time in two trials, and including ten selected fecal C. jejuni isolated from the same 328 
sheep with the six bile C. jejuni isolates). The 39 C. jejuni isolates were clustered into five 329 
different clusters (Figure 3), apart from four isolates that were non-typeable by PFGE because 330 
they were not digestible by KpnI. The four non-typeable isolates included one CIPS bile isolate 331 
and three selected CIPS fecal isolates from the same three sheep with bile isolates. Type A is the 332 
predominant genotype and accounted for 69.2% (27/39) of the analyzed isolates. This 333 
predominant cluster include both CIPR and CIPS C. jejuni isolated from fecal and bile samples. 334 
MLST results indicated that all but two C. jejuni isolates in type A belonged to ST2862 (Figure 335 
2). One of the two non-ST2862 isolates was a CIPR C. jejuni (ID: 0993), which showed only one 336 
base difference in gltA with ST2862. After submitting the sequence to the MLST database, the 337 
new gltA allele was assigned to gltA586 (in comparison it is gltA2 in ST2862) and the isolate was 338 
assigned a new ST type ST9380. The other non-ST2862 isolate was also a new ST type 339 
(ST9379) and was a bile isolate (ID: 292). The detailed information of MLST profiles in the two 340 
isolates were presented in Table S2. The other four PFGE patterns, types B, C, D and E, 341 
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consisted of 8 C. jejuni isolates. Type B belonged to ST982, while types C, D, and E all 342 
belonged to ST52 (Figure 3). For the selected bile and fecal C. jejuni isolates from the same 343 
sheep, the situation was more diverse comparing with the C. coli isolates (Figure 3). Bile and 344 
fecal isolates from each of the animals with an ID number 898, 346 and 604 shared the same 345 
PFGE and MLST profiles, while the bile and fecal isolates from other three animals were of 346 
different PFGE or MLST types (ID292, the same PFGE with different ST types; ID961, different 347 
PFGE types but with the same ST type; ID610, different PFGE types with different ST types).  348 
Altogether, the PFGE and MLST findings indicated predominant genotypes in both C. coli 349 
and C. jejuni, suggesting clonal expansion may have been involved in the dissemination of both 350 
C. coli and C. jejuni in sheep. 351 
Point mutations in gyrA 352 
Based on different PFGE and MLST types, eight CIPR C. coli and four CIPR C. jejuni 353 
isolates were selected for determination of the point mutations in gyrA. All the CIPR C. coli 354 
isolates harbored a single Thr-86-Ile mutation in GyrA without any other amino acids changes in 355 
this region (Figure 2). For the CIPR C. jejuni isolates, three had the Thr-86-Ile point mutation 356 
alone, and one carried the Thr-86-Ile mutation plus the Ser-22-Gly, Asn-203-Ser and Arg-285-357 
Lys changes (Figure 3). These results are consistent with the known role of the Thr-86-Ile 358 
mutation in mediating CIP resistance in Campylobacter. 359 
Discussion 360 
Results from this study revealed high prevalence of TET-resistant Campylobacter spp. and 361 
CIPR C. coli in sheep derived from two commercial farms. These animals were naturally infected 362 
and already carried antibiotic-resistant Campylobacter on the day of arrival (Tables 1, 2, and 3). 363 
Subsequent treatment with in-feed tetracycline in a research setting did not affect the overall 364 
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prevalence, antimicrobial susceptibility profiles, and species distribution of Campylobacter as 365 
there were no statistically significant differences (p > 0.05) between the feed medicated and non-366 
medicated groups. However, the quantitative CFU counts in bile and gallbladder mucosa 367 
collected at the end of the trials revealed higher total CFUs in the medicated group than the non-368 
medicated group (P < 0.05), suggesting that tetracycline treatment may promote Campylobacter 369 
colonization in gallbladder. The exact reason for this effect is unknown, but it is known that 370 
tetracyclines undergo significant enterohepatic circulation, resulting in significant concentration 371 
of tetracyclines in bile, which may inhibit competitive bacterial organisms and confer a 372 
colonization advantage for tetracycline-resistant Campylobacter. Since similar numbers of 373 
animals received therapeutic treatment in both groups, it is likely that the effect is attributable to 374 
in-feed use of tetracycline. Regardless of the reasons, the enhanced colonization of gallbladder 375 
may give Campylobacter an advantage in the spread to other organs or dissemination back to the 376 
intestinal tract.  377 
In fecal samples, C. jejuni accounted for 68.6% of the total isolates (Table 1), while in bile 378 
samples the isolates were almost exclusively C. jejuni (98.0%), suggesting that C. jejuni has a 379 
higher tropism to bile or a higher ability to reach to and adapt within the gallbladder. Previous 380 
studies observed similar prevalence between C. jejuni and C. coli in sheep gallbladders (38, 39), 381 
however, these previous studies were conducted in a different country and it is possible that 382 
differences in sheep production practices or genetic variability of Campylobacter strains may 383 
influence gallbladder colonization by the organism. Bile is harmful to bacteria, however, 384 
Campylobacter utilizes the multidrug efflux pump CmeABC for bile resistance (40-43). The 385 
exact reason for the predominance of C. jejuni in gallbladder as observed in this study is 386 
unknown and remains to be investigated in future studies. Interestingly, C. jejuni clone SA was 387 
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not detected in the sheep examined in this study. This clone is a predominant cause of 388 
Campylobacter-associated ovine abortions and is also distributed in feedlot and dairy cattle in 389 
the U.S. (23, 44). A recent study also reported identification of Clone SA in Grenada (45). The 390 
lack of clone SA detection in this study is not entirely surprising as we have previously found 391 
that the distribution of clone SA is highly variable from farm to farm (25). Thus, it was likely 392 
that the two farms where the sheep were derived from did not harbor this particular C. jejuni 393 
strain.  394 
Except for FQs and tetracycline, the Campylobacter isolates examined in this study were 395 
generally susceptible to other tested antimicrobials (Table 3). All but one of the tested 396 
Campylobacter isolates from fecal and bile samples were resistant to tetracycline. This finding 397 
further strengthens the result from our previous study on Campylobacter carriage in sheep 398 
slaughterhouse, which revealed the resistance rate to tetracycline was already 83.3% (25). In this 399 
study, the in-feed tetracycline medication did not further influence the prevalence of tetracycline-400 
resistant Campylobacter due to the fact that tetracycline resistance in the sheep was already very 401 
high (virtually 100%) at the beginning of the treatment. Thus, the result should be interpreted 402 
precautiously. Given the high prevalence of tetracycline-resistant Campylobacter on sheep farms 403 
in the U.S., the use of tetracycline as a mean to control Campylobacter-induced sheep abortion 404 
would have a limited impact. In fact, tetracycline medication may have facilitated the persistence 405 
of tetracycline-resistant Campylobacter on sheep farms. Results from this study further underline 406 
the need for improved tetracycline stewardship in sheep to reduce the prevalence of tetracycline-407 
resistant Campylobacter.    408 
A significant finding of this work is the detected high prevalence of CIPR C. coli (95%), 409 
while CIP resistance in the sheep C. jejuni isolates remained low (1.7%) (Table 3). The 410 
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difference between C. coli and C. jejuni is unlikely due to variation in their susceptibility to 411 
fluoroquinolones as CIPR C. jejuni is also common in other animal species (6, 7). The high-level 412 
prevalence of CIPR C. coli in sheep was unexpected as this class of antibiotics is not used in 413 
sheep production in the United States. A recent study on cattle Campylobacter reported CIP 414 
resistance rates of 35.4% in C. jejuni and 77.3% in C. coli (15). This could be explained by the 415 
fact that FQ antibiotics are labeled for treatment of respiratory disease in cattle in the U.S. The 416 
reason for the detected high incidence of CIPR C. coli in sheep in this study is unknown, but 417 
there is a possibility of transmission of CIPR Campylobacter from cattle to sheep. Although the 418 
sampled sheep farms were not adjacent to other animal species, they could get Campylobacter 419 
through birds, flies, or other transmission vehicles. However, if this were the sole case, we would 420 
have also observed an increased prevalence of CIPR C. jejuni in sheep as it is also common in 421 
cattle. It is possible that the CIPR C. coli strains were introduced to sheep by chance and 422 
something on these farms favored the selection of CIPR C. coli, contributing to its overall high 423 
prevalence in sheep. It should be pointed out that fluoroquinolones are also approved for use in 424 
swine and were used in poultry prior to 2005 in the U.S. Thus, the possibility that sheep acquired 425 
CIPR C. coli from other animal species rather than cattle can't be totally excluded. 426 
To determine the genetic relatedness of the Campylobacter isolates, we conducted PFGE and 427 
MLST analyses, which are commonly used for genotyping of Campylobacter (20, 46-48). PFGE 428 
typing of 24 representative C. coli revealed a limited number of types and that the majority 429 
(18/24) of the CIPR C. coli isolates were grouped into a single type (type Ⅲ; Figure 2), which 430 
was confirmed by MLST to be a single ST (ST902). It is worthwhile to note that type Ⅲ 431 
included isolates from different and geographically distant farms and from different sampling 432 
times, suggesting that this genotype is stable and is prevalent on different sheep farms. Also, bile 433 
 o
n
 April 2, 2019 by guest
http://aem
.asm
.org/
D
ow
nloaded from
 
 20 
 
and fecal isolates from the same sheep shared the same PFGE type and ST type. The other two 434 
PFGE types belonged to ST827 (type Ⅰ) and ST1068 (type Ⅱ). C. coli ST827 has been previously 435 
reported, sometimes to be the most common ST in both sheep and cattle (49, 50), while ST1068 436 
is more often found in cattle (15, 50, 51). Moreover, ST1068 was also identified among swine C. 437 
coli isolates, sometimes to be the most predominant ST type (51-53). In addition, the three 438 
identified STs (ST902, ST827 and ST1068) all belong to the ST-828 complex (Figure 2). 439 
Although the specific prevalent ST types vary in different species, C. coli isolates of ST-828 440 
complex, the most prevalent CC (clonal complex) for C. coli, have been frequently reported in 441 
published studies from different countries and different sources, including poultry, cattle, sheep, 442 
swine and even humans (15, 54-57). Our results confirmed the prevalence of this CC and the 443 
existence of specific endemic ST type among animals in different regions.  444 
The 39 representative C. jejuni isolates examined by PFGE typing in this study, they were 445 
grouped into five clusters (Figure 3), with the exception of four that were not typeable by PFGE 446 
because KpnI failed to digest appropriately. Similar to the C. coli result, the majority (27/39) of 447 
the tested C. jejuni isolates was grouped into one cluster (type A), which was confirmed by 448 
MLST to be a single ST (ST2862) except for two isolates, suggesting it was the predominant C. 449 
jejuni clone in sheep. This clone included both CIPS and CIPR C. jejuni isolated from both fecal 450 
and bile samples that were collected from different farms (trials 1 and 2) and different sampling 451 
times (Figure 3), indicating this genotype was commonly disseminated in sheep. The other four 452 
PFGE types belonged to ST982 (type B) and ST52 (types C, D and E). ST982 accounted for 453 
20.8% (10/48) of the C. jejuni isolates in a previous study involving a lamb slaughterhouse and 454 
was also reported in cattle (15, 25, 58). ST-52 was reported sporadically in C. jejuni from 455 
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different countries and sources, including ruminants (45-47, 57, 59, 60). Both ST2862 and 456 
ST982, belong to CC21, which is the most prevalent CC in C. jejuni. 457 
To examine the possible transmission of Campylobacter between sheep and cattle, we 458 
selected some cattle Campylobacter isolates identified in our previous study (15) to compare 459 
with the sheep Campylobacter isolates identified in this study. The PFGE and MLST results 460 
revealed that ST902 (the predominant C. coli genotype in sheep identified in this study) with the 461 
same PFGE pattern was also found in the cattle C. coli (Figure S1a), although the predominant 462 
ST was ST1068 in cattle (15). Here, we also identified ST1068 in sheep C. coli (Figure 2), which 463 
had a similar PFGE pattern with cattle C. coli (Figure S1b). These findings further suggest the 464 
possible transmission of FQR C. coli (e.g. ST902 and ST1068) between cattle and sheep. In 465 
contrast to the C. coli isolates, the predominant C. jejuni genotype ST2862 (Figure 3) in sheep 466 
was not previously identified in cattle in the U.S. (15, 26, 58). Although C. jejuni ST982 has 467 
been found in cattle (15), their PFGE patterns were quite different from the sheep isolates 468 
(Figure S1c). Thus, the genetic relatedness between sheep and cattle C. jejuni isolates were not 469 
as clear as for C. coli. 470 
In Campylobacter, FQ-resistance is mediated by point mutations in the QRDR of DNA 471 
gyrase (GyrA) and the function of the CmeABC multidrug efflux pump (8, 61). The most 472 
frequent mutation associated with FQ resistance in Campylobacter is Thr-86-Ile, followed by 473 
Asp-90-Asn, Thr-86-Lys, Thr-86-Ala, Thr-86-Val, Asp-90-Tyr, and Ala-70-Thr (8, 62). 474 
Additionally, double mutations including Thr-86-Ile/Pro-104-Ser and Thr-86-Ile/Asp-90-Asn 475 
have also been associated with FQ resistance in Campylobacter (63). The mutation of Asn-203-476 
Ser is also known to confer FQ resistance along with the Thr-86-Ile mutation (64). Ser-22-Gly 477 
has not been linked to FQ resistance in Campylobacter and there was no evidence that Asn-203-478 
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Ser and Arg-285-Lys alone were associated with the FQ resistance phenotype (15). In this study, 479 
all examined FQR Campylobacter isolates harbored the Thr-86-Ile mutation in GyrA, while one 480 
isolate also carried the Ser-22-Gly, Asn-203-Ser and Arg-285-Lys mutations, consistent with the 481 
known role of the Thr-86-Ile change (alone or along with other mutations) in CIP resistance. 482 
In summary, we observed high prevalence of tetracycline-resistant Campylobacter and FQR 483 
C. coli in commercial sheep operations, regardless of in-feed medication with tetracycline. 484 
Although the medication increased the total Campylobacter CFU counts in the sheep gallbladder, 485 
it did not affect overall prevalence, genotypes, or antimicrobial susceptibility profiles of the 486 
Campylobacter isolates under the conditions employed in this study. The sheep harbored 487 
predominant genotypes of C. jejuni (ST2862) and C. coli (ST902). Of particular note, the FQR C. 488 
coli clones in the sheep (both ST902 and ST1068) were genetically linked to the isolates 489 
previously identified in cattle, suggesting the possibility of dynamic transmission of FQR C. coli 490 
between sheep and cattle. However, there are several limitations in this study. First, the work 491 
was a controlled laboratory treatment study, and the pre-existing high prevalence of tetracycline-492 
resistant Campylobacter limited our ability to analyze the effect of the in-feed medication on 493 
development of tetracycline resistance. Second, the sheep were derived only from two 494 
commercial farms and the sample sizes were not particularly large. Thus, the findings may not 495 
represent the overall situation with sheep Campylobacter in the U.S. Despite these limitations, 496 
the findings provide new and useful information on sheep Campylobacter. Since ruminants are 497 
important reservoirs for Campylobacter and a significant source of foodborne 498 
campylobacteriosis in humans, enhanced efforts should be directed toward the development of 499 
interventions to reduce prevalence and transmission of FQR Campylobacter in sheep and cattle. 500 
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Figure 1. Campylobacter counts (Log10 CFUs/ml) in bile (a) and gallbladder mucosal (b) 756 
samples in the non-medicated and medicated groups. Each bar represents the average log10 757 
CFUs per mL (+/-SEM). "*" indicates significant difference from the non-medicated group (P < 758 
0.05). The data include samples from both trials.  759 
 760 
 761 
 762 
 763 
 764 
Figure 2 PFGE patterns of representative C. coli isolates in sheep. T1 and T2: Trials 1 and 2; W1, W2, 765 
and W3: 1st, 2nd and 3rd week; CIP: ciprofloxacin. NC: at necropsy; ND: not done. #: The TET susceptible 766 
C. coli. The bold fonts in animal IDs indicate the animals from which both bile and fecal isolates were 767 
typed. 768 
 769 
 770 
 771 
 772 
 773 
 774 
Figure 3 PFGE patterns of representative C. jejuni isolates in sheep. T1 and T2: Trials 1 and 2; W1, W2, 775 
and W3: 1st, 2nd and 3rd week; CIP: ciprofloxacin. NC: at necropsy; ND: not done. *indicated newly 776 
assigned ST types. The bold fonts in animal IDs indicate the animals from which both bile and fecal 777 
isolates were typed. Four of the C. jejuni isolates were non-typeable by PFGE and are not shown.  778 
 779 
 780 
 781 
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Table 1. Isolation rates of Campylobacter in sheep fecal samples 
Sampling 
Time 
Trial 1 (6/21/2017-7/6/2017) Trial 2 (7/13/2017-7/26/2017) 
All fecal samples 
1st week (6/21) 2nd week (6/29) 3rd week (7/6) 1st week (7/13) 2nd week (7/21) 3rd week (7/26) 
Groups NM M T NM M T NM M T NM M T NM M T NM M T NM M T ᵻ 
No. isolates 
(%) 
34 
(52.3) 
31 
(47.7) 
65 
(100) 
34 
(50.0) 
34 
(50.0) 
68 
(100) 
32 
(51.6) 
30 
(48.4) 
62 
(100) 
36 
(51.4) 
34 
(48.6) 
70 
(100) 
33 
(50.0) 
33 
(50.0) 
66 
(100) 
33 
(47.1) 
37 
(52.9) 
70 
(100) 
202 
(50.4) 
199 
(49.6) 
401 
(100) 
C. jejuni 
(%) 
30 
(58.8) 
21 
(41.2) 
51 
(78.5) 
27 
(49.1) 
28 
(50.9) 
55 
(80.9) 
20 
(46.5) 
23 
(53.5) 
43 
(69.4) 
19 
(51.4) 
18 
(48.6) 
37 
(52.9) 
24 
(55.8) 
19 
(44.2) 
43 
(65.2) 
25 
(54.3) 
21 
(45.7) 
46 
(65.7) 
145 
(52.7) 
130 
(47.3) 
275 
(68.6) 
C. coli (%) 
5 
(29.4) 
12 
(70.6) 
17 
(26.2) 
8 
(47.1) 
9 
(52.9) 
17 
(25.0) 
13 
(56.5) 
10 
(43.5) 
23 
(37.1) 
19 
(52.8) 
17 
(47.2) 
36 
(51.4) 
10 
(40.0) 
15 
(60.0) 
25 
(37.9) 
12 
(37.5) 
20 
(62.5) 
32 
(45.7) 
67 
(44.7) 
83 
(55.3) 
150 
(37.4) 
NM: non-medicated group; M: medicated group; T: total. ᵻ24 fecal samples were positive both for C. jejuni and C. coli. 
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Table 2. Overall prevalence of Campylobacter in sheep bile samples* 
Sampling Time Trial 1 (6/21/2017-7/6/2017) Trial 2 (7/13/2017-7/26/2017) All bile samples 
Groups NM M T NM M T NM M T 
No. isolates 
(%) 
28 (50.9) 27 (49.1) 55 (100) 22 (51.2) 21 (48.8) 43 (100) 50 (51.0) 48 (49.0) 98 (100) 
C. jejuni (%) 28 (50.9) 27 (49.1) 55 (100) 22 (53.7) 19 (46.3) 41 (95.3) 50 (52.1) 46 (47.9) 96 (98.0) 
C. coli (%) 0 (0) 0 (0) 0 (0) 0 (0) 2 (100.0) 2 (4.7) 0 (0.0) 2 (100.0) 2 (2.0) 
NM: non-medicated group; M: medicated group; T: total. *Bile samples were collected at necropsy at the end of the two trials. 
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Table 3 Antimicrobial resistance profiles and rates of the tested Campylobacter isolates from fecal samples 
Antibiotics Tetracycline Ciprofloxacin Nalidixic acid Gentamicin 
Trial 1 
C. jejuni 
Non-medicated 100.0% (60/60) 0.0% (0/60) 3.3% (2/60) 1.7% (1/60) 
Medicated 100.0% (60/60) 0.0% (0/60) 5.0% (3/60) 0.0% (0/60) 
Total 100.0% (120/120) 0.0% (0/120) 4.2% (5/120) 0.8% (1/120) 
C. coli 
Non-medicated 100.0% (25/25) 100.0% (25/25) 100.0% (25/25) 0.0% (0/25) 
Medicated 100.0% (25/25) 100.0% (25/25) 100.0% (25/25) 0.0% (0/25) 
Total 100.0% (50/50) 100.0% (50/50) 100.0% (50/50) 0.0% (0/50) 
Trial 2 
C. jejuni 
Non-medicated 100.0% (58/58) 1.7% (1/58) 3.4% (2/58) 0.0% (0/58) 
Medicated 100.0% (58/58) 5.2% (3/58) 0.0% (0/58) 0.0% (0/58) 
Total 100.0% (116/116) 3.4% (4/116) 1.7% (2/116) 0.0% (0/116) 
C. coli 
Non-medicated 96.0% (24/25) 88.0% (22/25) 88.0% (22/25) 0.0% (0/25) 
Medicated 100.0% (26/26) 92.3% (24/26) 92.3% (24/26) 0.0% (0/26) 
Total 98.0% (50/51) 90.2% (46/51) 90.2% (46/51) 0.0% (0/51) 
Total 
C. jejuni 
Non-medicated 100.0% (118/118) 0.8% (1/118) 3.4% (4/118) 0.8% (1/118) 
Medicated 100.0% (118/118) 2.5% (3/118) 2.5% (3/118) 0.0% (0/118) 
Total 100.0% (236/236) 1.7% (4/236) 3.0% (7/236) 0.4% (1/236) 
C. coli 
Non-medicated 98.0% (49/50) 94.0% (47/50) 94.0% (47/50) 0.0% (0/50) 
Medicated 100.0% (51/51) 96.1% (49/51) 96.1% (49/51) 0.0% (0/51) 
Total 99.0% (100/101) 95.0% (96/101) 95.0% (96/101) 0.0% (0/101) 
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